-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, May 17 News On May 14, Beilu Pharmaceutical's iodixanol injection passed the consistency evaluation and became the sixth company that has passed the evaluation of the product.
Iodixanol is the main product of the contrast agent market.
In 2020, the terminal sales of public medical institutions in China will exceed 4 billion yuan, and Hengrui Medicine will occupy 51.
19% of the market share.
Iodixanol injection has been included in the fifth batch of centralized procurement, and the competition pattern of 1 original research + 6 review has been determined.
Iodixanol is the main product of the contrast agent market.
In 2020, the terminal sales of public medical institutions in China will exceed 4 billion yuan, and Hengrui Medicine will occupy 51.
19% of the market share.
Iodixanol injection has been included in the fifth batch of centralized procurement, and the competition pattern of 1 original research + 6 review has been determined.
Iodixanol injection is an X-ray contrast agent, suitable for adult cardiovascular angiography, cerebrovascular angiography, peripheral arteriography, abdominal angiography, urography and CT enhanced examination; children cardiovascular angiography, urography and CT enhanced examination.
According to data from Menet.
com, the domestic market for iodixanol has continued to rise in recent years.
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal iodixanol sales Over 4 billion yuan, an increase of 13.
90% year-on-year.
Among them, Hengrui Pharmaceuticals accounted for 51.
19% of the market share, and General Electric accounted for 28.
95%.
com, the domestic market for iodixanol has continued to rise in recent years.
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal iodixanol sales Over 4 billion yuan, an increase of 13.
90% year-on-year.
Among them, Hengrui Pharmaceuticals accounted for 51.
19% of the market share, and General Electric accounted for 28.
95%.
Terminal iodixanol sales in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
The first company to review iodixanol injection is Stellite , the leading iodine contrast agent raw material drug.
Zhengda Tianqing Pharmaceutical Group, Yangtze River Pharmaceutical, Nanjing Zhengda Tianqing, and Hengrui Pharmaceutical have also reviewed this product one after another, Beilu Pharmaceutical It is the sixth company that has passed the evaluation of this variety.
Zhengda Tianqing Pharmaceutical Group, Yangtze River Pharmaceutical, Nanjing Zhengda Tianqing, and Hengrui Pharmaceutical have also reviewed this product one after another, Beilu Pharmaceutical It is the sixth company that has passed the evaluation of this variety.
Hengrui Medicine is the leading domestic iodine contrast agent preparation, and iodixanol injection is its main product.
According to Hengrui's annual report, in 2020, the company's contrast agent product revenue was 3.
63 billion yuan, an increase of 12.
40% year-on-year, with a gross profit margin of 72.
41%.
Among them, the sales of iodixanol injection was 4.
2276 million pieces, a year-on-year increase of 13.
92%.
In the centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding and procurement of medicines , the company's winning price range for the product was 569.
99-721 yuan/piece, and the total actual purchase volume of medical institutions was 3.
6455 million pieces.
pharmnet.
com.
cn/news/yyzb/" target="_blank">
According to Hengrui's annual report, in 2020, the company's contrast agent product revenue was 3.
63 billion yuan, an increase of 12.
40% year-on-year, with a gross profit margin of 72.
41%.
Among them, the sales of iodixanol injection was 4.
2276 million pieces, a year-on-year increase of 13.
92%.
In the centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding and procurement of medicines , the company's winning price range for the product was 569.
99-721 yuan/piece, and the total actual purchase volume of medical institutions was 3.
6455 million pieces.
pharmnet.
com.
cn/news/yyzb/" target="_blank">
The iodixanol injection was included in the fifth batch of centralized procurement, which will have an impact on the stock market of Hengrui Medicine's product.
With Beilu Pharmaceutical's over-evaluation of this product, the competitive pattern of centralized procurement of iodixanol injection has been set, with 1 original researcher + 6 over-evaluated.
With Beilu Pharmaceutical's over-evaluation of this product, the competitive pattern of centralized procurement of iodixanol injection has been set, with 1 original researcher + 6 over-evaluated.
Medical Network, May 17 News On May 14, Beilu Pharmaceutical's iodixanol injection passed the consistency evaluation and became the sixth company that has passed the evaluation of the product.
Iodixanol is the main product of the contrast agent market.
In 2020, the terminal sales of public medical institutions in China will exceed 4 billion yuan, and Hengrui Medicine will occupy 51.
19% of the market share.
Iodixanol injection has been included in the fifth batch of centralized procurement, and the competition pattern of 1 original research + 6 review has been determined.
Iodixanol is the main product of the contrast agent market.
In 2020, the terminal sales of public medical institutions in China will exceed 4 billion yuan, and Hengrui Medicine will occupy 51.
19% of the market share.
Iodixanol injection has been included in the fifth batch of centralized procurement, and the competition pattern of 1 original research + 6 review has been determined.
Iodixanol injection is an X-ray contrast agent, suitable for adult cardiovascular angiography, cerebrovascular angiography, peripheral arteriography, abdominal angiography, urography and CT enhanced examination; children cardiovascular angiography, urography and CT enhanced examination.
According to data from Menet.
com, the domestic market for iodixanol has continued to rise in recent years.
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal iodixanol sales Over 4 billion yuan, an increase of 13.
90% year-on-year.
Among them, Hengrui Pharmaceuticals accounted for 51.
19% of the market share, and General Electric accounted for 28.
95%.
com, the domestic market for iodixanol has continued to rise in recent years.
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal iodixanol sales Over 4 billion yuan, an increase of 13.
90% year-on-year.
Among them, Hengrui Pharmaceuticals accounted for 51.
19% of the market share, and General Electric accounted for 28.
95%.
Terminal iodixanol sales in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
The first company to review iodixanol injection is Stellite , the leading iodine contrast agent raw material drug.
Zhengda Tianqing Pharmaceutical Group, Yangtze River Pharmaceutical, Nanjing Zhengda Tianqing, and Hengrui Pharmaceutical have also reviewed this product one after another, Beilu Pharmaceutical It is the sixth company that has passed the evaluation of this variety.
Zhengda Tianqing Pharmaceutical Group, Yangtze River Pharmaceutical, Nanjing Zhengda Tianqing, and Hengrui Pharmaceutical have also reviewed this product one after another, Beilu Pharmaceutical It is the sixth company that has passed the evaluation of this variety.
Hengrui Medicine is the leading domestic iodine contrast agent preparation, and iodixanol injection is its main product.
According to Hengrui's annual report, in 2020, the company's contrast agent product revenue was 3.
63 billion yuan, an increase of 12.
40% year-on-year, with a gross profit margin of 72.
41%.
Among them, the sales of iodixanol injection was 4.
2276 million pieces, a year-on-year increase of 13.
92%.
In the centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding and procurement of medicines , the company's winning price range for the product was 569.
99-721 yuan/piece, and the total actual purchase volume of medical institutions was 3.
6455 million pieces.
pharmnet.
com.
cn/news/yyzb/" target="_blank">
According to Hengrui's annual report, in 2020, the company's contrast agent product revenue was 3.
63 billion yuan, an increase of 12.
40% year-on-year, with a gross profit margin of 72.
41%.
Among them, the sales of iodixanol injection was 4.
2276 million pieces, a year-on-year increase of 13.
92%.
In the centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding and procurement of medicines , the company's winning price range for the product was 569.
99-721 yuan/piece, and the total actual purchase volume of medical institutions was 3.
6455 million pieces.
pharmnet.
com.
cn/news/yyzb/" target="_blank">
The iodixanol injection was included in the fifth batch of centralized procurement, which will have an impact on the stock market of Hengrui Medicine's product.
With Beilu Pharmaceutical's over-evaluation of this product, the competitive pattern of centralized procurement of iodixanol injection has been set, with 1 original researcher + 6 over-evaluated.
With Beilu Pharmaceutical's over-evaluation of this product, the competitive pattern of centralized procurement of iodixanol injection has been set, with 1 original researcher + 6 over-evaluated.
Medical Network, May 17 News On May 14, Beilu Pharmaceutical's iodixanol injection passed the consistency evaluation and became the sixth company that has passed the evaluation of the product.
Iodixanol is the main product of the contrast agent market.
In 2020, the terminal sales of public medical institutions in China will exceed 4 billion yuan, and Hengrui Medicine will occupy 51.
19% of the market share.
Iodixanol injection has been included in the fifth batch of centralized procurement, and the competition pattern of 1 original research + 6 review has been determined.
Iodixanol is the main product of the contrast agent market.
In 2020, the terminal sales of public medical institutions in China will exceed 4 billion yuan, and Hengrui Medicine will occupy 51.
19% of the market share.
Iodixanol injection has been included in the fifth batch of centralized procurement, and the competition pattern of 1 original research + 6 review has been determined.
Iodixanol injection is an X-ray contrast agent, suitable for adult cardiovascular angiography, cerebrovascular angiography, peripheral arteriography, abdominal angiography, urography and CT enhanced examination; children cardiovascular angiography, urography and CT enhanced examination.
According to data from Menet.
com, the domestic market for iodixanol has continued to rise in recent years.
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal iodixanol sales Over 4 billion yuan, an increase of 13.
90% year-on-year.
Among them, Hengrui Pharmaceuticals accounted for 51.
19% of the market share, and General Electric accounted for 28.
95%.
Hospital hospital hospitalcom, the domestic market for iodixanol has continued to rise in recent years.
In 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal iodixanol sales Over 4 billion yuan, an increase of 13.
90% year-on-year.
Among them, Hengrui Pharmaceuticals accounted for 51.
19% of the market share, and General Electric accounted for 28.
95%.
Terminal iodixanol sales in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
The first company to review iodixanol injection is Stellite , the leading iodine contrast agent raw material drug.
Zhengda Tianqing Pharmaceutical Group, Yangtze River Pharmaceutical, Nanjing Zhengda Tianqing, and Hengrui Pharmaceutical have also reviewed this product one after another, Beilu Pharmaceutical It is the sixth company that has passed the evaluation of this variety.
Enterprise business enterpriseZhengda Tianqing Pharmaceutical Group, Yangtze River Pharmaceutical, Nanjing Zhengda Tianqing, and Hengrui Pharmaceutical have also reviewed this product one after another, Beilu Pharmaceutical It is the sixth company that has passed the evaluation of this variety.
Hengrui Medicine is the leading domestic iodine contrast agent preparation, and iodixanol injection is its main product.
According to Hengrui's annual report, in 2020, the company's contrast agent product revenue was 3.
63 billion yuan, an increase of 12.
40% year-on-year, with a gross profit margin of 72.
41%.
Among them, the sales of iodixanol injection was 4.
2276 million pieces, a year-on-year increase of 13.
92%.
In the centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding and procurement of medicines , the company's winning price range for the product was 569.
99-721 yuan/piece, and the total actual purchase volume of medical institutions was 3.
6455 million pieces.
pharmnet.
com.
cn/news/yyzb/" target="_blank">
Drugs Drugs Drugspharmnet. According to Hengrui's annual report, in 2020, the company's contrast agent product revenue was 3.
63 billion yuan, an increase of 12.
40% year-on-year, with a gross profit margin of 72.
41%.
Among them, the sales of iodixanol injection was 4.
2276 million pieces, a year-on-year increase of 13.
92%.
In the centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding and procurement of medicines , the company's winning price range for the product was 569.
99-721 yuan/piece, and the total actual purchase volume of medical institutions was 3.
6455 million pieces.
pharmnet.
com.
cn/news/yyzb/" target="_blank">
com.
cn/news/yyzb/" target="_blank"> Tenderpharmnet.
com.
cn/news/yyzb/" target="_blank"> Tender Tender
The iodixanol injection was included in the fifth batch of centralized procurement, which will have an impact on the stock market of Hengrui Medicine's product.
With Beilu Pharmaceutical's over-evaluation of this product, the competitive pattern of centralized procurement of iodixanol injection has been set, with 1 original researcher + 6 over-evaluated.
Medicine Medicine Medicine With Beilu Pharmaceutical's over-evaluation of this product, the competitive pattern of centralized procurement of iodixanol injection has been set, with 1 original researcher + 6 over-evaluated.
